



T: 0131-244-2528  
E: irene.fazakerley@gov.scot

**IMMEDIATE MESSAGE TO:**

1. Directors of Pharmacy
2. Medical Directors NHS Boards

17 May 2022

Dear Healthcare Professional,

**DRUG ALERT CLASS 2 – 23 2022 – CLASS 2 MEDICINES RECALL – ACTION WITHIN 48 HOURS – QUADRANT PHARMACEUTICALS LTD – MEFENAMIC ACID 500MG FILM COATED TABLETS**

Please see drug alert for onward transmission as below

Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Primary Care Pharmacists

Please could Medical Directors arrange to forward this alert on to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

**IRENE FAZAKERLEY**  
**Medicines Policy Team**





# MEDICINES RECALL

## CLASS 2 MEDICINES RECALL

Action Within 48 Hours  
Pharmacy/Wholesaler Level Recall

Date: 17 May 2022

EL (22)A/23

Our Ref: MDR 183-04/22

Dear Healthcare Professional,

### Quadrant Pharmaceuticals Ltd

#### Mefenamic Acid 500mg film coated tablets

PLPI 20774/1591

Batch Number	Company's Reference	Expiry Date	Pack Size	First Distributed
107082	6949U	04/2023	30	03/2022

Active Pharmaceutical Ingredient: Mefenamic acid

#### Brief description of the problem

Quadrant Pharmaceuticals Ltd are recalling the affected batch as a precautionary measure, due to observations of a defective layer of film coating in some tablets, resulting in the tablet core being partially exposed.

#### Advice for healthcare professionals

Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

#### Advice to patients

No further action is required by patients as this is a Pharmacy and Wholesaler level recall.

Although the Marketing Authorisation Holder have not received any reports of adverse reactions related to the issue above, patients who experience adverse reactions or insufficient control of symptoms should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

#### Further Information

For more information, medical or supply enquiries, please contact [joanne.fishwick@maxearn.co.uk](mailto:joanne.fishwick@maxearn.co.uk) or [radoslaw.bandomir@maxearn.co.uk](mailto:radoslaw.bandomir@maxearn.co.uk)

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

**Defective Medicines Report Centre**  
**10 South Colonnade**  
**Canary Wharf**  
**London**  
**E14 4PU**  
**Telephone +44 (0)20 3080 6574**  
[DMRC@mhra.gov.uk](mailto:DMRC@mhra.gov.uk)